Washington University in St. Louis, School of Medicine
Welcome,         Profile    Billing    Logout  
 6 Trials 
12 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Conway, Charles R
NCT03736538: Nitrous Oxide- Suicidal Ideation

Enrolling by invitation
1
50
US
Nitrous Oxide, Laughing Gas, Placebo gas
Washington University School of Medicine, American Foundation for Suicide Prevention
Major Depressive Disorder, Depression, Mood Disorders, Suicidal Ideation
06/24
07/24
NCT02942368: Adaptive tDCS for Treatment-Resistant MDD

Active, not recruiting
N/A
25
US
tDCS
Washington University School of Medicine
Depressive Disorder, Treatment-Resistant
06/24
06/24
ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting
N/A
100
US
Sham-stimulation, Active-stimulation
Abbott Medical Devices
Treatment Resistant Depression
04/27
04/29
UNCOVER, NCT04753385: The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes

Terminated
N/A
138
US
LivaNova
Treatment Resistant Depression
09/24
09/24
RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting
N/A
6800
US
Vagus Nerve Stimulation (VNS), VNS
LivaNova
Treatment Resistant Depression
02/28
12/30
Lucey, Brendan
NCT05728736: Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

Withdrawn
2
30
US
Lemborexant 25 mg, Dayvigo, Placebo, inactive pill, sugar pil
Brendan Lucey, Eisai Inc.
Alzheimer Disease
09/23
10/23
NCT06274528: DORA and LP in Alzheimer's Disease Biomarkers

Recruiting
2
201
US
Lemborexant 10 mg, DAYVIGO, Lemborexant 20mg, Placebo
Washington University School of Medicine, National Institutes of Health (NIH), Eisai Inc., National Institute on Aging (NIA)
Alzheimer Disease
03/29
03/29
SToP-AD, NCT04629547: Sleep Trial to Prevent Alzheimer's Disease

Recruiting
2
200
US
Suvorexant 20 mg, Belsomra, Placebo, inactive pill, sugar pill
Washington University School of Medicine, Good Ventures, Merck Sharp & Dohme LLC
Sleep, Alzheimer Disease
05/26
05/26
Neuman, Brian J
NCT06368245: Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions

Not yet recruiting
N/A
1244
Europe, Canada, Japan, US, RoW
long-segment posterior TL instrumented fusion
AO Foundation, AO Spine
Spinal Fusion
12/27
07/29
Toedebusch, Cristina
NCT05728736: Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau

Withdrawn
2
30
US
Lemborexant 25 mg, Dayvigo, Placebo, inactive pill, sugar pil
Brendan Lucey, Eisai Inc.
Alzheimer Disease
09/23
10/23
NCT06274528: DORA and LP in Alzheimer's Disease Biomarkers

Recruiting
2
201
US
Lemborexant 10 mg, DAYVIGO, Lemborexant 20mg, Placebo
Washington University School of Medicine, National Institutes of Health (NIH), Eisai Inc., National Institute on Aging (NIA)
Alzheimer Disease
03/29
03/29
SToP-AD, NCT04629547: Sleep Trial to Prevent Alzheimer's Disease

Recruiting
2
200
US
Suvorexant 20 mg, Belsomra, Placebo, inactive pill, sugar pill
Washington University School of Medicine, Good Ventures, Merck Sharp & Dohme LLC
Sleep, Alzheimer Disease
05/26
05/26

Download Options